English
Tablet coating defects represent a massive operational risk in pharmaceutical manufacturing facilities. A single compromised batch leads to severe material loss, immediate regulatory scrutiny, and extended production downtime.
The coating process dictates the final quality of solid dosage manufacturing. It provides the primary barrier for active pharmaceutical ingredients (APIs), blocking oxygen, light, and moisture.
Unresolved tableting defects cause severe financial and compliance headaches for pharmaceutical and nutraceutical manufacturers. Batch rejections, failed friability tests, and unexpected machine downtime directly impact profitability and production schedules.
The selection of compression equipment dictates a facility's production bottlenecks, product consistency, and time-to-market for solid dose manufacturing.